<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="preparation" /><meta name="keywords" content="Filgrastim; Zarzio" /><meta name="IX" content="Filgrastim; Zarzio" /><title>Zarzio®: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="204126.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="204126.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=204126.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2076.htm">9 Nutrition and blood</a> &gt; <a href="4843.htm">9.1 Anaemias and some other blood disorders</a> &gt; <a href="4926.htm">9.1.6 Drugs used in neutropenia</a> &gt; <a href="4927.htm">FILGRASTIM</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="4926.htm" title="Previous: 9.1.6 Drugs used in neutropenia">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="23073.htm" title="Next: LENOGRASTIM">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a392033.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Filgrastim</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Blood Formation, Coagulation, and Thrombosis 20:00 &gt; Hematopoietic Agents 20:16</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/14677-z.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Filgrastim</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: F &gt; Interactions of Filgrastim</p></div></li></ul><ul><li><h3>British National Formulary (9)</h3></li><li><a href="4926.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">9.1.6 Drugs used in neutropenia</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 9 Nutrition and blood &gt; 9.1 Anaemias and some other blood disorders</p></div></li><li><a href="4927.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">FILGRASTIM</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 9 Nutrition and blood &gt; 9.1 Anaemias and some other blood disorders &gt; 9.1.6 Drugs used in neutropenia</p></div></li><li><a href="4928.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Neupogen®</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 9 Nutrition and blood &gt; 9.1 Anaemias and some other blood disorders &gt; 9.1.6 Drugs used in neutropenia &gt; FILGRASTIM</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22granulocyte-colony+stimulating+factor%22%22filgrastim%22%22filgrastim%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (9)</a></li></ul><ul><li><h3>BNF for Children (8)</h3></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/4926.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">9.1.6 Drugs used in neutropenia</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 9 Nutrition and blood &gt; 9.1 Anaemias and some other blood disorders</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/4927.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">FILGRASTIM</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 9 Nutrition and blood &gt; 9.1 Anaemias and some other blood disorders &gt; 9.1.6 Drugs used in neutropenia</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/4928.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Neupogen®</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 9 Nutrition and blood &gt; 9.1 Anaemias and some other blood disorders &gt; 9.1.6 Drugs used in neutropenia &gt; FILGRASTIM</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22granulocyte-colony+stimulating+factor%22%22filgrastim%22%22filgrastim%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (8)</a></li></ul><ul><li><h3>Handbook on Injectable Drugs</h3></li><li><a href="http://www.medicinescomplete.com/mc/hid/2010/a593010.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Filgrastim</a><div class="breadcrumb"><p><strong>Handbook on Injectable Drugs</strong> &gt; Monographs &gt; F</p></div></li></ul><ul><li><h3>Injectable Drugs Guide (2)</h3></li><li><a href="http://www.medicinescomplete.com/mc/idg/2010/f03-mn0001.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Filgrastim (G-CSF, r-metHuCSF)</a><div class="breadcrumb"><p><strong>Injectable Drugs Guide</strong> &gt; Injectable Drugs Guide &gt; Monographs &gt; F</p></div></li><li><a href="http://www.medicinescomplete.com/mc/idg/2010/L04-mn0001.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Lenograstim (recombinant human granulocyte colony-stimulating factor, rHuG-CSF)</a><div class="breadcrumb"><p><strong>Injectable Drugs Guide</strong> &gt; Injectable Drugs Guide &gt; Monographs &gt; L</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/ms-14677-z.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Filgrastim</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Blood Products Plasma Expanders and Haemostatics &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/04537.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Granulocyte Colony-Stimulating Factor</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; G &gt; GR</p></div></li></ul><ul><li><h3>Stockley's Drug Interactions</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E0E0E6E3E0R0D1521.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Filgrastim</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; F</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1 id="_4927">FILGRASTIM</h1><div id="pC" class="jN"><h2 class="cBO">(Recombinant human granulocyte-colony stimulating factor,
G-CSF)</h2><div class="cAJ"><span class="cAD">Additional information</span> interactions (<a href="41001i565.htm" title="Go to appendix 1">Filgrastim</a>).</div><div class="cAF"><h2>Indications</h2> <p class="cAF">(specialist use only) reduction in duration of neutropenia and incidence
of febrile neutropenia in cytotoxic chemotherapy for malignancy (except
chronic myeloid leukaemia and myelodysplastic syndromes); reduction
in duration of neutropenia (and associated sequelae) in myeloablative
therapy followed by bone-marrow transplantation; mobilisation of peripheral
blood progenitor cells for harvesting and subsequent autologous or
allogeneic infusion; severe congenital neutropenia, cyclic neutropenia,
or idiopathic neutropenia and history of severe or recurrent infections
(distinguish carefully from other haematological disorders, consult
product literature); persistent neutropenia in advanced HIV infection</p></div><div class="cAF"><h2>Cautions</h2> <p class="cAF">see <a title="target-block: Drugs used in neutropenia cautions" href="4926.htm#_4926.1">notes above</a>; also
regular morphological and cytogenetic bone-marrow examinations recommended
in severe congenital neutropenia (possible risk of myelodysplastic
syndromes or leukaemia); secondary acute myeloid leukaemia; osteoporotic bone disease (monitor bone
density if given for more than 6 months); <b>interactions:</b> Appendix 1 (<span>filgrastim</span>)</p></div><div class="cAF"><h2>Contra-indications</h2> <p class="cAF">severe congenital neutropenia
(Kostmann’s syndrome) with abnormal cytogenetics</p></div><div class="cAF"><h2>Pregnancy</h2> <p class="cAF">see <a title="BNF:target-block: Drugs in neutropenia - pregnancy " href="4926.htm#_204125">notes above</a></p></div><div class="cAF"><h2>Breast-feeding</h2> <p class="cAF">see <a title="BNF:target-block: Drugs in neutropenia - breast-feeding" href="4926.htm#_208186">notes above</a></p></div><div class="cAF"><h2>Side-effects</h2> <p class="cAF">see <a title="BNF:target-block: neutropenia side effects" href="4926.htm#_204275">notes above</a>; also
mucositis, splenic enlargement, hepatomegaly, transient hypotension,
epistaxis, urinary abnormalities (including dysuria, proteinuria,
and haematuria), osteoporosis, exacerbation of rheumatoid arthritis,
anaemia, transient decrease in blood glucose, pseudogout, and raised
uric acid; <i>very rarely</i> splenic rupture</p></div><div class="cAF"><h2>Dose</h2> <p class="cR">Cytotoxic-induced neutropenia, preferably <span class="cU">by subcutaneous
injection</span><i> or </i><span class="cU">by intravenous infusion</span> (over 30 minutes), <span class="cAK">adult</span> and <span class="cAK">child</span>, 500 000 units/kg daily started at least 24
hours after cytotoxic chemotherapy, continued until neutrophil count
in normal range, usually for up to 14 days (up to 38 days in acute
myeloid leukaemia)</p><p class="cR">Myeloablative therapy followed by bone-marrow transplantation, <span class="cU">by intravenous infusion</span> over 30 minutes or over 24 hours <i>or </i><span class="cU">by subcutaneous infusion</span> over 24 hours,
1 million units/kg daily, started at least 24 hours following cytotoxic
chemotherapy (and within 24 hours of bone-marrow infusion), then adjusted
according to neutrophil count (consult product literature)</p><p class="cR">Mobilisation of peripheral blood progenitor cells for autologous
infusion, used alone, <span class="cU">by subcutaneous injection</span><i> or </i><span class="cU">by subcutaneous infusion</span> over 24 hours,
1 million units/kg daily for 5–7 days; used following adjunctive myelosuppressive
chemotherapy (to improve yield), <span class="cU">by subcutaneous injection</span>, 500 000 units/kg daily, started the day after completing chemotherapy
and continued until neutrophil count in normal range; for timing of
leucopheresis consult product literature</p><p class="cR">Mobilisation of peripheral blood progenitor cells in normal
donors for allogeneic infusion, <span class="cU">by subcutaneous injection</span>, <span class="cAK">adult</span> under 60 years and <span class="cAK">child</span> over 16 years, 1 million units/kg daily for
4–5 days; for timing of leucopheresis consult product literature</p><p class="cR">Severe chronic neutropenia, <span class="cU">by subcutaneous injection</span>, <span class="cAK">adult</span> and <span class="cAK">child</span>, in severe congenital neutropenia, initially 1.2 million units/kg
daily in single or divided doses (initially 500 000 units/kg daily
in idiopathic or cyclic neutropenia), adjusted according to response
(consult product literature)</p><p class="cR">Persistent neutropenia in HIV infection, <span class="cU">by subcutaneous
injection</span>, initially 100 000 units/kg daily, increased as
necessary until neutrophil count in normal range (usual max. 400 000 units/kg
daily), then adjusted to maintain neutrophil count in normal range
(consult product literature)</p></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="4928.htm#_4928" title="Neupogen®">Neupogen®</a></li><li><a href="213575.htm#_213575" title="Nivestim®">Nivestim®</a></li><li><a href="201279.htm#_201279" title="Ratiograstim®">Ratiograstim®</a></li><li><a href="213576.htm#_213576" title="Tevagrastim®">Tevagrastim®</a></li><li class="jN" id="_204126" style="margin: 0 0 0 20px;"><h1 class="title">Zarzio®<span> (<a href="appendix-112803-S.htm#m647">Sandoz</a>)</span> <a href="204285.htm" title="Report adverse reaction(s)"><img class="cK" src="images/blacktri_s.png" alt="Black triangle" /></a> <img class="cJ" src="images/pom_l.png" title="Prescription-only Medicine" alt="Prescription-only Medicine" /></h1><div class="cAY"><span class="cAB">Injection</span>, prefilled syringe, filgrastim,
net price 30 million-units (300 micrograms)/0.5 mL = £59.00; 48 million-units
(480 micrograms)/0.5 mL = £94.00<div class="cAQ"><div class="cAR cAU"><h3>Note</h3> <p class="cAX"><a title="target-block: Biosimilar medicines" href="29404.htm#_200789">Biosimilar medicine</a></p></div></div></div></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="4926.htm">Previous: 9.1.6 Drugs used in neutropenia</a> | <a class="top" href="204126.htm#">Top</a> | <a accesskey="]" href="23073.htm">Next: LENOGRASTIM</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>